TARGANTA

Targanta, Inc. is a biopharmaceutical company focused on developing and commercializing antibacterial agents... Targanta's latest-stage antibacterial drug, oritavancin, is a semisynthetic glycopeptide with potent bactericidal activity against nearly all clinically relevant, difficult-to-treat Gram-positive infections. Based on two successful Phase III clinical trials with oritavancin, Targanta intends to file an NDA for complicated skin/skin structure infections in early 2008. Additional indications, including nosocomial pneumonia and catheter-related bacteremia, will be sought on an ongoing basis.

Also known as: Targanta Therapeutics, Targanta Therapeutics Corp., Targanta Therapeutics, Inc., Targanta, Inc.

Primary location: Cambridge United States